Latest Avidity Biosciences News & Updates

See the latest news and media coverage for Avidity Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.

Avidity Biosciences

Biotechnology company developing targeted RNA therapeutics

aviditybiosciences.com

Headquarters: San Diego, United States
Company type: Private company
Number of employees: 400–500
Industry: Pharmaceuticals

Last updated Today

Latest news about Avidity Biosciences

In short: Avidity Biosciences completed its $12B acquisition by Novartis, which later faced trial setbacks with del-desiran and saw shares slide.

Company announcements

June 12 Avidity Biosciences

Novartis completes Avidity Biosciences acquisition

The deal closed on February 27, 2026. Novartis thanks its team and partners for their support during this significant corporate milestone.

February 27 Avidity Biosciences

Novartis completes acquisition of Avidity Biosciences

The companies join forces to expand RNA therapeutic possibilities for patients.

12 November 2025 Avidity Biosciences

Avidity Biosciences honors VP Alexander Titus with award

Titus receives the Biocom California Life Science Catalyst Award for his leadership in integrating AI and data science into drug discovery.

26 October 2025 Avidity Biosciences

Avidity Biosciences enters a definitive merger agreement with Novartis

Novartis gains the neuroscience pipeline and RNA platform, while Avidity’s cardiology division spins off into a new public entity.

Media coverage

September 23 Ad Hoc News

Avidity Biosciences stock leaves Nasdaq after Novartis deal

Avidity Biosciences stock left Nasdaq after Novartis completed its USD 12 billion acquisition on February 27, 2026. The deal offered USD 72.00 per share.

September 22 Daily Dental Warehouse

Novartis faces September’s fourth trial disappointment with ALS drug - Drug Discovery World (DDW)

Del-desiran is one of three AOC therapies added to the Novartis neuromuscular pipeline through the acquisition of Avidity Biosciences.

September 20 note

[Special Report] Lessons from Avidity's P3 Failure Faced by Novartis and the Depths of the Sironax "BDM" Acquisition: The Inevitability of Shifting from "Delivery Competition ...

In gene therapy, nucleic acid medicine, and biologics drug discovery, the greatest bottleneck remains the "extrahepatic delivery" technology that safely and efficiently transports therapeutic molecules...

September 8 Financial Times

Novartis shares slide after drug for muscular disease fails trial

Novartis shares tumbled 12 per cent on Tuesday after the Swiss pharmaceutical group said that a closely watched drug designed ...

Never miss news about Avidity Biosciences

Track Avidity Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Avidity Biosciences competitors & trending companies

Browse news for competitors to Avidity Biosciences and other trending companies.